G1 Therapeutics Inc Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) Masimo...

G1 Therapeutics Inc:

G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced the appointments of Jack Bailey to its Board of Directors and Soma Gupta as its Chief Commercial Officer (CCO).

- Jack Bailey appointed to Board of Directors- Soma Gupta joins as Chief Commercial Officer- Company reports inducement grant under Nasdaq Listing Rule...

G1 Therapeutics (NASDAQ:GTHX) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, ValuE

Barclays PLC boosted its stake in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 702.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exc

Q4 2019 G1 Therapeutics Inc Earnings Call

Abbot Financial Management Inc. purchased a new stake in G1 Therapeutics Inc (NASDAQ:GTHX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The

Zacks Investment Research upgraded shares of G1 Therapeutics (NASDAQ:GTHX) from a sell rating to a hold rating in a research report sent to investors on Tuesday, Zacks.com reports. According to Zacks,

G1 Therapeutics (NASDAQ:GTHX) was downgraded by research analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, ValuEngine reports. G

G1 Therapeutics Inc (NASDAQ:GTHX) – Stock analysts at Wedbush decreased their Q1 2020 earnings per share (EPS) estimates for G1 Therapeutics in a note issued to investors on Thursday, February 27th.

Fmr LLC boosted its position in shares of G1 Therapeutics Inc (NASDAQ:GTHX) by 0.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commi

G1 Therapeutics (NASDAQ:GTHX) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Friday, BidAskClub reports. S

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on G1 Therapeutics (GTHX) and GW Pharma (GWPH) with bullish

Cowen & Co. analyst Chris Shibutani assigned a Buy rating to G1 Therapeutics (GTHX) yesterday. The company's shares closed last Monday at $17.46,